Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,405,839 | 765,340 | 857,525 | 1,394,191 | 1,255,620 |
| Depreciation Amortization | 3,622,170 | 2,493,002 | 1,253,288 | 3,772,738 | 2,577,302 |
| Accounts receivable | 177,775 | 260,345 | 331,773 | -297,693 | -387,119 |
| Accounts payable and accrued liabilities | -51,669 | -76,446 | -191,682 | -115,157 | -248,429 |
| Other Working Capital | -237,575 | -316,560 | -828,835 | -953,099 | -1,811,888 |
| Other Operating Activity | 1,368,330 | 911,146 | 64,350 | 1,710,172 | 1,638,004 |
| Operating Cash Flow | $6,284,870 | $4,036,827 | $1,486,419 | $5,511,152 | $3,023,489 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -801,067 | -555,036 | -286,543 | -1,002,910 | -716,069 |
| Net Acquisitions | 213,265 | 191,141 | 202,108 | 63,294 | -157,142 |
| Purchase Of Investment | -102,570 | -5,794 | -1,484 | -629,402 | -185,818 |
| Sale Of Investment | 41,925 | 31,933 | 7,783 | 176,075 | 154,871 |
| Purchase Sale Intangibles | -1,434,063 | -271,218 | -187,370 | -890,333 | -613,398 |
| Other Investing Activity | -1,373,860 | -215,261 | -150,896 | -899,757 | -649,063 |
| Investing Cash Flow | $-2,022,306 | $-553,017 | $-229,032 | $-2,292,701 | $-1,553,221 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 3,419,390 | 3,577,208 | 1,266,530 | 6,761,436 | 6,595,882 |
| Debt Repayment | -815,152 | -3,176,729 | -864,542 | -5,174,921 | -1,902,927 |
| Common Stock Repurchased | -335,420 | -350,900 | -356,061 | -12,421 | -12,609 |
| Dividend Paid | -1,970,241 | -1,047,758 | -1,002,536 | -1,932,216 | -986,970 |
| Other Financing Activity | -3,024,210 | -544,612 | -526,201 | -2,609,456 | -2,310,924 |
| Financing Cash Flow | $-2,725,632 | $-1,542,791 | $-1,482,810 | $-2,967,578 | $1,382,451 |
| Exchange Rate Effect | 216,925 | 74,317 | -16,802 | -11,121 | -164,579 |
| Beginning Cash Position | 2,503,235 | 2,618,768 | 2,657,280 | 3,021,480 | 3,067,260 |
| End Cash Position | 4,257,090 | 4,634,105 | 2,415,055 | 3,261,232 | 5,755,400 |
| Net Cash Flow | $1,753,856 | $2,015,336 | $-242,225 | $239,752 | $2,688,140 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,284,870 | 4,036,827 | 1,486,419 | 5,511,152 | 3,023,489 |
| Capital Expenditure | -842,667 | -598,454 | -330,600 | -1,003,213 | -716,324 |
| Free Cash Flow | 5,442,204 | 3,438,373 | 1,155,819 | 4,507,939 | 2,307,165 |